Aldevron and Integrated DNA Technologies (IDT) are at the forefront of a non-viral gene editing framework designed to support programs across in vivo and ex vivo therapeutic modalities. In this webinar, we show how emphasis is placed on editing specificity, off-target assessment and manufacturability to support IND-enabling studies.